Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!
Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are present in lung adenocarcinomas responsive to the EGFR inhibitors gefitinib and erlotinib. Two types of mutations account for 90% of mutation cases: short in-frame deletions of exon 19 and specific point mutations in codon 858 (L858R) of exon 21.